浙江医学2011，Vol.33Issue(5)：615-618,4.
过氧化物酶增殖物激活受体激动剂对同型半胱氨酸所致内皮细胞凋亡的调节作用
The Effect of Peroxisome Proliferator-activated receptor-γ agonists on homocysteine-induced apoptosis in human umbilical vein endothelial cells
摘要
Abstract
Objective To investigate the effect and mechanism ofperoxisome proliferators activated receptor (PPAR) γ agonists on homocystein (Hcy)- induced apoptosis in endothelial cells.Methods Human umbilical vein endothelial cells (HUVECs) were cultured primarily.Cellapoptosis was evaluated by AnnexinV/propidium iodide staining and flow cytometry.Reactive oxygen species (ROS) were determined with 2',7'- Dichlorofluorescin Diacetate (DCF- DA) by FACS.Activation oftranscription factors nuclear factor (NF)- κB was assessed by an electrophoretic mobility shift assay.Results Pretreatment of cells with pioglitazone (10-6mol/L, 10-5mol/L, 10-4mol/L) inhibited Hcy- induced cell apoptosis in a dose- dependent manner.The maximum effect of pioglitazone was observed at a concentration of 10-4mol/L.15d- PGJ2 inhibited Hcy- induced cellapoptosis.Moreover, pioglitazone and 15d- PGJ2 attenuated apoptosis and generation of ROS induced by Hcy, respectively.Further, we observed that N- acetylcysteine inhibited cell apoptosis induced by Hcy as did the PPARγ agonists.Hcy treatment activated the redox- sensitive transcription factors NF- κB, and pretreatment with 15d- PGJ2 and pioglitazone reduced the Hcy- induced DNA- binding activity of NF- κB.Conclusion Our data demonstrate that the PPARγ agonists pioglitazone and 15d- PGJ2 attenuate Hcy- induced apoptosis in HUVECs, which may be mediated by the modulation of ROS release and the redox- sensitive transcription factor NF- κB.关键词
同型半胱氨酸/细胞凋亡/过氧化物酶体增殖物激活受体γ激动剂/活性氧/内皮细胞Key words
Homocysteine / Apoptosis / Peroxisome proliferator- activated receptor- γ agonist / Reactive oxygen species Endothelial cells引用本文复制引用
李莉,龚仕金,严静,虞意华,戴海文,许强宏,陈进,蔡国龙..过氧化物酶增殖物激活受体激动剂对同型半胱氨酸所致内皮细胞凋亡的调节作用[J].浙江医学,2011,33(5):615-618,4.基金项目
浙江省科技厅重大项目(2006C13018) （2006C13018）
老年医学学科群建设科研计划招标项目(2009ZB005) （2009ZB005）
浙江省医药卫生科学研究基金计划(2010KYB017) （2010KYB017）
